Document is current
Any future updates will be listed below
-
Authors
Gorantla, Sivahari P. https://orcid.org/0009-0001-2977-3870
Oelschläger, Lorenz https://orcid.org/0009-0002-8960-5040
Prince, Gerin https://orcid.org/0009-0005-0438-7972
Osius, Jasmin
Kolluri, Suresh Babu
Maluje, Yamil
Fähnrich, Anke
Ernst, Nancy
Barbosa Gulde, Alanis
Ludwig, Ralf Joachim
Gemoll, Timo
Fliedner, Stephanie
Walter, Wencke https://orcid.org/0000-0002-5083-9838
Haferlach, Torsten https://orcid.org/0000-0003-0196-2837
Gebauer, Niklas https://orcid.org/0000-0003-0566-4554
Busch, Hauke https://orcid.org/0000-0003-4763-4521
Duyster, Justus
von Bubnoff, Nikolas https://orcid.org/0000-0001-9593-8947
-
Funding
Funding for this research was provided by:
BK-Wegener Stiftung, DFG
DAAD Scholarship for Doctoral Programme
American Autoimmune Related Diseases Association
Autoimmune Predisease
- License Information
-
More Information
Article History
Received: 7 November 2024
Revised: 7 March 2025
Accepted: 26 March 2025
First Online: 23 April 2025
Competing interests
: NvB received honoraria by Novartis and BMS. The remaining authors declare no competing financial interests.
: All the methods were performed in accordance with the relevant guidelines and regulations. The study was approved by the internal scientific review board of MLL. All patients had given written informed consent to the use of genetic and clinical data according to the Declaration of Helsinki.
